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OBJECTIVES: To develop a quantitative algorithm 
that transforms the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS), which is the most frequently used 
instrument to evaluate different clinical dimensions of
Parkinson’s Disease (PD), into EuroQoL (EQ-5D) values.
METHODS: A total of 157 PD patients (mean age: 
67yrs., 63% male, mean total UPDRS: 44, mean EQ-5D:
0.74) were recruited in a prospective study at a German
movement disorders center. Both EQ-5D and UPDRS
were evaluated at baseline in 124 patients. Spearman cor-
relation coefﬁcient (R) was used to test whether total
UPDRS score, sub scores (U2,U3,U4), and other patient
characteristics were univariately associated with EQ-5D.
A transformation algorithm with UPDRS sub scores as
predictors and EQ-5D as outcome was derived using mul-
tivariate regression analysis. Goodness-of-ﬁt was deter-
mined by adjusted R-square and the Hosmer-Lemeshow
method. RESULTS: In the univariate analysis, all UDPRS
sub scores were signiﬁcantly (p < 0.05) correlated with
clinical stage on the Hoehn & Yahr (HY) scale. Signiﬁ-
cant inverse correlation (all p < 0.001) was found between
EQ-5D and total UPDRS (R = -0.67), U2 (R = -0.63),
U3 (R = -0.60), U4 (R = -0.59), and HY stage (R =
-0.52). Multivariate analysis showed that 52% of the
variance in EQ-5D could be explained by the following
equation: EQ-5D = (99.62 - 1.36 ¥ U2 - 0.13 ¥ U3 -
1.66 ¥ U4)/100. The Hosmer-Lemeshow test showed
good predictive power. Using different mathematical
functions (e.g., log, logit, square) of predictors, utilities
or disutilities, and inclusion of interaction terms did not
substantially increase adjusted R-square. CONCLU-
SIONS: We suggest a simple, parsimonious, and easily
feasible algorithm for the transformation of UPDRS
scores into EQ-5D-based utilities. The purpose of this
function is not to predict individual quality of life, but
mean utilities for populations with a speciﬁc UPDRS 
conﬁguration, which may be used in the evaluation of
intervention’s overall effectiveness or cost-effectiveness.
This algorithm can be applied to existing UPDRS data
sets and used in cost-utility analyses of health technolo-
gies.
VV7
WILLINGNESS TO PAY FOR HEARING AIDS IN
THE NETHERLANDS
Grutters J, Chenault M,Anteunis L, Joore M
University Hospital Maastricht, Maastricht, Netherlands
OBJECTIVE: To measure the maximum willingness to
pay (WTP) for a hearing aid (HA) in the Netherlands in
both hard of hearing persons and persons accompanying
them. METHODS: In a survey 151 clients and 55 persons
accompanying them were asked about their maximum
WTP for a HA, the out of pocket (OoP) payment for the
HA(s) currently ﬁtted, and some perceptions about the
reimbursement of HAs, when visiting their HA dispenser.
RESULTS: The mean age of the clients was 70 years, and
of the accompanying persons 62 years. In both groups
approximately 50% was male, 20% earned an income
below €1150 and 7% an income above €3400, and two
third were compulsory insured. Most accompanying
persons were either the partner (63%) or a child (24%)
of the client. The mean OoP payment for the current
HA(s) ﬁtted was €461 (sd 392) per HA. Of both the
clients and the accompanying persons 46% found it
unjust to some extent to pay any OoP contribution for a
hearing aid. Over 90% of the clients and the accom-
panying persons perceived that abolition of the reim-
bursement would be very problematic. Mean maximum
WTP per HA was €277 (sd 296) for the clients and €207
(sd 264) for the accompanying persons. CONCLUSION:
It can be concluded that there is considerable aversion to
an increase of OoP payments as a result of the abolition
of the reimbursement. Mean maximum WTP found in
this study is considerably lower than the ﬁgure observed
in a US study: $982 per HA (Chisolm & Abrams, 2001).
Mean maximum WTP per HA is also lower than the
actual OoP contribution for the HAs currently ﬁtted. This
might reﬂects the difference between revealed and stated
preferences, or may be a result of shifted preference.
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OBJECTIVE: The Vaizey score is a tool to assess the
severity of faecal incontinence and to determine treatment
effect. As clinicians develop the score, it may not reﬂect
the overall health impact of faecal incontinence. This
study investigates the association between the Vaizey
score and health-related utility before patients received
treatment. METHODS: Baseline data from a prospective
diagnostic cohort study were used to evaluate the incon-
tinence score and the health utility of patients. The Vaizey
score (0 (continent)—24 (totally incontinent)) consists 
of items concerning the type (solid, liquid, gas) and 
frequency of faecal incontinence, the use of pads and 
constipating medication, and the amount of social inval-
idation. Health utility was calculated by a simple additive
model using EuroQol5D data on mobility, self-care, daily
activities, pain/discomfort and anxiety/depression.
RESULTS: Data from 89 (13 men; mean age 59) patients
were analysed. On average, patients suffered from incon-
tinence for 8.7 years, the mean Vaizey score was 18.5 and
mean utility 0.82. Lower Vaizey scores coincided with
higher health utility values (Spearman’sr = -0.316, p <
0.01). Patients indicating any problems on a EuroQol
dimension showed higher Vaizey scores than patients
without problems; however, this was only signiﬁcant for
daily activities (Mann-Whitney U = 597.5 p < 0.001) and
anxiety/depression (Mann-Whitney U = 685, p < 0.05).
CONCLUSION: Before treatment the Vaizey score was
signiﬁcantly correlated with total utility and was associ-
ated with two dimensions of the EuroQol: daily activities
and anxiety/depression. Further studies will investigate
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whether this signiﬁcant relation is still present after
receiving treatment. If this relation is absent potential
mechanisms (e.g. coping style) that could explain dis-
crepancies will be investigated.
GI DISEASE
GD1
COST-UTILITY ANALYSIS OF “ON DEMAND”
RABEPRAZOLE AND ESOMEPRAZOLE FOR
SYMPTOMATIC GASTRO OESOPHAGEAL
REFLUX DISEASE
Hughes DA1, Dubois D2
1University of Liverpool, Liverpool, United Kingdom; 2Johnson
& Johnson Pharmaceutical Services, LLC, Beerse, Belgium
OBJECTIVES: To model the 1-year cost-utility of
rabeprazole and esomeprazole “on demand” (prn) treat-
ment for symptomatic gastro oesophageal reﬂux disease
from the perspective of the UK National Health Service.
METHODS: Data relating to treatment discontinuation
due to inadequate heartburn control were extracted from
two clinical trials; one comparing rabeprazole 10mg with
placebo prn and the other comparing esomeprazole 
20mg, 40mg and placebo prn. Survival data (proportion
of patients continuing therapy) were ﬁtted to Weibull
functions, and adjusted for comparability according to
placebo data. Data from the trials on drug intake, use of
antacids as rescue medication and severity of heartburn
symptoms were also used for the analysis. Health care
resource utilization included annual frequency of general
practitioner and gastroenterologist consultation and of
upper GI endoscopy, annual number of drug prescriptions
and pharmacy dispensing fees. These were priced accord-
ing to the latest NHS costs. Health state utilities were
derived from a study that assessed EQ-5D utilities in 1003
patients with GERD, and related utility scores to dura-
tion and severity of symptoms. A probabilistic model was
employed that sampled from Weibull distributions for
survival time, assigned Poisson distributions to annual
frequency of events, Beta distributions to utilities and
Dirichlet distribution to severity of heartburn. RESULTS:
The mean total costs of therapy with rabeprazole 10mg,
esomeprazole 20mg and 40mg were £93, £103, and
£121, respectively. The associated utility scores were,
respectively, 0.866, 0.861 and 0.860. CONCLUSIONS:
For non-erosive reﬂux oesophagitis, treatment with
rabeprazole 10mgprn is less expensive than with either
20mg or 40mg esomeprazole prn. All three alternatives
are comparable in terms of their effectiveness.
GD2
A COST CONSEQUENCE ANALYSIS OF A NEW
ENDOSCOPIC, INJECTABLE TREATMENT AND
EXISTING INTERVENTIONS IN GASTRO-
OESOPHAGEAL REFLUX DISEASE
Boler A1, Wenk-Lang A2, Howard P1
1Heron Evidence Development, Letchworth, Hertfordshire,
United Kingdom; 2Boston Scientiﬁc International, La Garenne
Colombes, France
OBJECTIVES: To compare the costs and consequences 
of Enteryx with Laparascopic Nissen Fundoplication
(LNF) and pharmacological therapy (PPIs) in patients
with Gastro-Oesophageal Reﬂux Disease (GORD). The
Enteryx Procedure is a new endoscopically injected
polymer-based treatment for GORD. METHODS: A
decision analytical approach was taken to model the
ability of the three interventions to successfully treat
patients with GORD. The model time horizon was one
year with an additional 5-year long-term perspective. The
clinical outcomes and the resource consumption data 
for PPIs were derived from the literature. A multicentre
clinical study of Enteryx provided the clinical outcomes
for Enteryx. Treatment outcomes following LNF were
sourced from the literature. Experienced UK experts pro-
vided resource consumption data for the Enteryx proce-
dure and LNF. Patients on pharmacological treatment
(PPIs) with relapse followed the recommended route of
moving to higher dose therapy for eight weeks and if still
not responding received a further eight weeks followed
by an endoscopy. RESULTS: At 1-year average costs per
patient were lower with Enteryx (£2683) than with LNF
(£4718). The cost of PPI treatment at 1 year amounted
to £394 for all patients and to £691 for patients needing
a higher dose of treatment. At 5 years, Enteryx patients
had a lower cost of £3004 per patient compared to LNF
(£4769) and high dose PPI users (£3457). The average
cost for all PPI users at 5 years was £1970. CONCLU-
SIONS: For those patients suitable for surgery, Enteryx
provides a less expensive option than LNF largely due to
the reduced hospitalisation and procedure costs. Due to
the recurrent nature of PPI treatment and cost, Enteryx
is a cost saving therapy in the long-term compared to
pharmacological therapy, especially for patients on high
maintenance dose.
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COSTS OF GASTROENTERITIS IN THE
NETHERLANDS
van den Brandhof WE1, De Wit GA1, de Wit MAS2,
van Duijnhoven YTHP1
1National Institute of Public Health, Bilthoven, Netherlands;
2National Institute of Public Health and the Environment,
Bilthoven, Netherlands
OBJECTIVES: To estimate the cost of illness and the
disease burden, in terms of disability adjusted life years
(DALYs), for gastroenteritis in the Netherlands in 1999.
METHODS: The study population consisted of a com-
munity-based prospective cohort study on gastroenteritis,
with a nested case-control study, in cooperation with the
Dutch sentinel general practice network. Cases with gas-
troenteritis identiﬁed in the cohorts were requested to
submit stool samples, complete a questionnaire on risk
factors and complete a medical diary for four weeks. In
this diary, cases reported daily about symptoms, absence
from work or school, use of medication and use of health
services, such as GP and hospital services. Health services
use and productivity losses were valued according to
